Download Immunosuppressive drugs: the first 50 years and a glance forward

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts

Drug discovery wikipedia, lookup

Nucleic acid analogue wikipedia, lookup

Deoxyribozyme wikipedia, lookup

Amino acid synthesis wikipedia, lookup

Artificial gene synthesis wikipedia, lookup

Peptide synthesis wikipedia, lookup

Signal transduction wikipedia, lookup

Biosynthesis wikipedia, lookup

Oligonucleotide synthesis wikipedia, lookup

Specialized pro-resolving mediators wikipedia, lookup

Lipid signaling wikipedia, lookup

Enzyme inhibitor wikipedia, lookup

Polyclonal B cell response wikipedia, lookup

Expression vector wikipedia, lookup

Natural product wikipedia, lookup

Paracrine signalling wikipedia, lookup

Metabolomics wikipedia, lookup

Pharmacometabolomics wikipedia, lookup

Mitogen-activated protein kinase wikipedia, lookup

MTOR inhibitors wikipedia, lookup

De novo protein synthesis theory of memory formation wikipedia, lookup

Transcript
Immunosuppressive drugs: the first 50 years and a glance forward.
Allison AC.
Immunopharmacology. 2000 May;47(2-3):63-83.
SurroMed Corporation, 1060 E. Meadow Circle, Palo Alto, CA 94303,
USA.
During the past 50 years, many immunosuppressive drugs have been described.
Often their mechanisms of action were established long after their discovery.
Eventually these mechanisms were found to fall into five groups:
(i) regulators of gene expression;
(ii) alkylating agents;
(iii) inhibitors of de novo purine synthesis;
(iv) inhibitors of de novo pyrimidine synthesis; and
(v) inhibitors of kinases and phosphatases.
Glucocorticoids exert immunosuppressive and anti-inflammatory activity mainly
by inhibiting the expression of genes for interleukin-2 and other mediators.
Cyclophosphamide metabolites alkylate DNA bases and preferentially suppress
immune responses mediated by B-lymphocytes.
Methotrexate and its polyglutamate derivatives suppress inflammatory responses
through release of adenosine; they suppress immune responses by inducing the
apoptosis of activated T-lymphocytes and inhibiting the synthesis of both purines
and pyrimidines.
Azathioprine metabolites inhibit several enzymes of purine synthesis.
Mycophenolic acid and Mizoribine inhibit inosine monophosphate
dehydrogenase, thereby depleting guanosine nucleotides. Mycophenolic acid
induces apoptosis of activated T-lymphocytes.
A Leflunomide metabolite and Brequinar inhibit dihydroorotate dehydrogenase,
thereby suppressing pyrimidine nucleotide synthesis.
Cyclosporine and FK-506 (Tacrolimus) inhibit the phosphatase activity of
calcineurin, thereby suppressing the production of IL-2 and other cytokines.
In addition, these compounds have recently been found to block the JNK
and p38 signaling pathways triggered by antigen recognition in T-cells.
In contrast, Rapamycin inhibits kinases required for cell cycling and responses to
IL-2. Rapamycin also induces apoptosis of activated T-lymphocytes.
Immunosuppressive and anti-inflammatory compounds in development include
inhibitors of p38 kinase and of the type IV isoform of cyclic AMP
phosphodiesterase which is expressed in lymphocytes and monocytes.